Utility of T-cell immunosequencing in distinguishing mycosis fungoides progression from treatment related cutaneous adverse events.
Utility of T-cell immunosequencing in distinguishing mycosis fungoides progression from treatment related cutaneous adverse events.
复制标题
DOI：
10.3389/fmed.2023.1243459
复制
发表时间：
2023
影响因子：
3.9
通讯作者：
Nikbakht, Neda
中科院分区：
文献类型：
--
作者：
Bhatti, Safiyyah;Joffe, Daniel;Banner, Lauren;Talasila, Sahithi;Mandel, Jenna;Lee, Jason;Porcu, Pierluigi;Nikbakht, Neda
关键词：
真菌样霉菌病（MF）患者的局部和全身药物的皮肤不良事件提出了诊断挑战，因为通常难以区分药物相关性皮疹和皮肤疾病进展。Mogamulizumab和meclothamine凝胶被批准用于MF治疗，这两种药物都可能导致与治疗相关的皮肤不良事件。从临床和组织学上区分mogamulizumab相关性皮疹（MAR）和氯胺酮凝胶相关性过敏性皮炎与MF进展通常具有挑战性。t细胞受体（TCR）的高通量测序（HTS），也称为免疫测序，可用于评估t细胞克隆性，以支持MF的诊断。在基线鉴定出恶性TCR克隆后，免疫测序可以高灵敏度地跟踪已建立的恶性TCR序列及其随时间的频率。因此，免疫测序克隆跟踪可以帮助区分疾病进展和治疗副作用。在这里，我们提出了一个病例系列来证明如何通过免疫测序监测恶性t细胞频率可以帮助诊断莫加单抗和氯胺酮凝胶皮肤不良事件。
Cutaneous adverse events of both topical and systemic drugs in patients with mycosis fungoides (MF) present a diagnostic challenge as it is often difficult to distinguish drug associated rash from disease progression in the skin. Mogamulizumab and mechlorethamine gel are approved treatments for MF, both of which can cause treatment related cutaneous adverse events. It can often be challenging to distinguish mogamulizumab associated rash (MAR) and mechlorethamine gel associated hypersensitivity dermatitis from MF progression both clinically and histologically. High-throughput sequencing (HTS) of the T-cell receptor (TCR), also known as immunosequencing, can be used to assess T-cell clonality to support a diagnosis of MF. After identification of the malignant TCR clone at baseline, immunosequencing can track the established malignant TCR sequence and its frequency over time with high sensitivity. As a result, immunosequencing clone tracking can aid in distinguishing disease progression from treatment side effects. Here, we present a case series to demonstrate how monitoring of the malignant T-cell frequency by immunosequencing can aid in diagnosis of mogamulizumab and mechlorethamine gel cutaneous adverse events.
登录
查看更多内容
影响因子：
17.1
作者：
de Masson A;O'Malley JT;Elco CP;Garcia SS;Divito SJ;Lowry EL;Tawa M;Fisher DC;Devlin PM;Teague JE;Leboeuf NR;Kirsch IR;Robins H;Clark RA;Kupper TS
通讯作者：
Kupper TS
影响因子：
1.7
作者：
Krishnasamy, Shalini;Correia, Emily;Nikbakht, Neda
通讯作者：
Nikbakht, Neda
影响因子：
3.4
作者：
Mahe E;Pugh T;Kamel-Reid S
通讯作者：
Kamel-Reid S
影响因子：
3.4
作者：
Musiek ACM;Rieger KE;Bagot M;Choi JN;Fisher DC;Guitart J;Haun PL;Horwitz SM;Huen AO;Kwong BY;Lacouture ME;Noor SJ;Rook AH;Seminario-Vidal L;Vermeer MH;Kim YH
通讯作者：
Kim YH
影响因子：
10.9
作者：
Hirotsu, Kelsey E.;Neal, Tatiana M.;Kwong, Bernice Y.
通讯作者：
Kwong, Bernice Y.